Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.

@article{Pahwa2014RandomizedTO,
  title={Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.},
  author={Rajesh Pahwa and Kelly E. Lyons and Robert A. Hauser and Stanley Fahn and Joseph Jankovic and Emmanuelle Pourcher and Ann Hsu and Martin O'Connell and Sherron H Kell and Suneel K. Gupta},
  journal={Parkinsonism & related disorders},
  year={2014},
  volume={20 2},
  pages={142-8}
}
OBJECTIVE IPX066 is an extended release carbidopa/levodopa formulation designed to rapidly attain and maintain therapeutic plasma concentrations for a prolonged duration, allowing dosing intervals of approximately 6 h. The objective was to assess the efficacy, safety, and impact on quality of life of IPX066 in the treatment of levodopa-naive Parkinson's disease (PD) patients. METHODS This was a randomized, double-blind, placebo-controlled, 30-week study of 381 levodopa-naïve patients assigned… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS